ADVOCACY, COMMUNICATIONS & FUNDRAISING
EUR 30 million secured in 2015
Since its inception in 2003, DNDi has secured EUR 395 million from loyal supporters and a growing network of new funders. As DNDi expands its R&D activities during its second decade, it is worth noting that a committed group of funders have provided significant long-term contributions to DNDi. The Bill & Melinda Gates Foundation (BMGF), UK Department for International Development (DFID), Médecins Sans Frontières (MSF), and the Dutch Ministry of Foreign Affairs (DGIS) account for approximately 73% of overall funds awarded since 2003 (see chart p. 67). Unrestricted and portfolio funding also remains highly important as it provides the necessary flexibility to easily react to opportunities or inherent attrition in our R&D activities. In an effort to maintain a sustainable funding pipeline, DNDi continues to make efforts to secure unrestricted and portfolio funding – representing 81% of DNDi’s funding resources. Innovative funding mechanisms continue to play an important role in DNDi’s funding strategy. The Global Health Innovation Technology (GHIT) Fund, a public-private partnership involving the Government of Japan, leading life science companies, the Bill & Melinda Gates Foundation, the Wellcome Trust, and UNDP, played an important role in supporting DNDi’s leishmaniasis and Chagas disease early discovery activities for an amount of ¥482 million in 2015. The most notable example of its success is the funding of the Japanese DNDi Japan portion of the Neglected Tropical Diseases Drug Discovery Booster consortium (see p. 21). Resulting from a process that began over a decade ago to ensure that R&D for public health needs of developing countries are prioritized, the creation by WHO Members States of a pilot pooled funding mechanism hosted by WHOTDR to foster innovation for neglected diseases provided EUR 2.3 million to DNDi’s Leishmaniasis Global R&D & Access i nitiative. This project is based on new R&D incentives and mechanisms following the core principles identified by the WHO Consultative Expert Working Group (CEWG) that includes affordability, effectiveness, efficiency, and equity.
DNDi Lastly, Brazil’s National Development Bank (Banco Nacional de DesenvolviLatin mento Econômico e Social – BNDES) granted R$ 3.5 million over three years in America
KEY CONTRIBUTIONS RECEIVED IN 2015
Dutch Ministry of Foreign Affairs (DGIS), The Netherlands (2015−2020)
The Directorate-General for International Cooperation provided portfolio funding support of EUR 16 million over 5 years for mycetoma, sleeping sickness, leishmaniasis, Chagas disease, and early discovery activities.
Department for International Development (DFID), UK (2015)
DFID provided supplemental funding of GBP 3 million for the year 2015 to support Chagas disease, VL & CL, sleeping sickness, discovery activities and attend scientific conferences to present DND i’s NTD research. DFID’s total contribution to date is GBP 64.4M. WHO-TDR awarded DND i EUR 2.34 million in support of a large-scale R&D project for leishmaniasis. The ‘Leishmaniasis Global R&D and Access Initiative’ project is based on the principle of de-linkage, which dissociates the cost of R&D from the price of the resulting products.
WHO-TDR Pool Funding (2015−2016)
French Development Agency (AFD), France (2015−2018)
AFD and DND i signed a partnership agreement of EUR 2 million for the development of a new, safe, and effective oral treatment to support efforts to control leishmaniasis in East Africa (Sudan, Ethiopia, Kenya, and Uganda).
Global Health Innovation Technology Fund, Japan (2015−2017)
The GHIT Fund invested EUR 3.2 million in a partnership between Takeda Pharmaceutical Company and DND i for the development of a new drug for visceral leishmaniasis based on a promising new series of aminopyrazoles. GHIT also awarded EUR 550K to DND i and three Japanese pharmaceutical companies in support of the NTD Drug Discovery Booster.